Evidence map›Paper›PMID 41394882›Full record

ReviewFrontiers in immunology2025

Hidden players of COVID-19: the evolving roles of SARS-CoV-2 accessory proteins.

Miguel Padilla-Blanco, Tránsito García-García, Juozas Grigas, Blanca D López-Ayllón, Juan J Garrido, María A Oliva, María Montoya

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Miguel Padilla-Blanco *Viral immunology laboratory, Biomedicine Department, BICS unit. Margarita Salas Centre for Biological Research (CIB-CSIC), Madrid, Spain.
Tránsito García-García *Department of Genetics, Immunogenomics and Molecular Pathogenesis Group, UIC Zoonoses and Emergent Diseases ENZOEM, University of Córdoba, Córdoba, Spain.
Juozas GrigasDepartment of Anatomy and Physiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Blanca D López-AyllónViral immunology laboratory, Biomedicine Department, BICS unit. Margarita Salas Centre for Biological Research (CIB-CSIC), Madrid, Spain.
Juan J Garrido *Department of Genetics, Immunogenomics and Molecular Pathogenesis Group, UIC Zoonoses and Emergent Diseases ENZOEM, University of Córdoba, Córdoba, Spain.
María A Oliva *Unit for the Development of Biological, Immunological and Chemical Drugs (BICS). Centro de Investigaciones Biológicas Margarita Salas (CSIC), Madrid, Spain.
María Montoya *Viral immunology laboratory, Biomedicine Department, BICS unit. Margarita Salas Centre for Biological Research (CIB-CSIC), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 accessory proteins (APs), particularly ORF3a and ORF9b, have emerged as key modulators of host-pathogen interaction and potential contributors to long COVID. Of the 13 predicted APs, only nine are expressed during infection - termed

Indexed as

COVID-19SARS-CoV-2Viral Regulatory and Accessory ProteinsAnimalsHost-Pathogen InteractionsHumansInterferon Type IViral ProteinsInterferon Type IViral ProteinsViral Regulatory and Accessory Proteinsaccessory proteinsCOVID-19omicron lineagesSARS-CoV-2viral pathobiology

Identifiers

PMID41394882
PMCPMC12698434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.